logo
Trending tickers: Oracle, TSMC, Rigetti Computing, Currys and Watches of Switzerland

Trending tickers: Oracle, TSMC, Rigetti Computing, Currys and Watches of Switzerland

Yahoo8 hours ago
Shares in Oracle (ORCL) notched a fresh high on Wednesday, after it was reported that OpenAI had signed a data centre deal with the technology company.
In an Securities and Exchange Commission filing on Monday, Oracle said that CEO Safra Catz was expected to tell colleagues that the company's current fiscal year was off to a "strong start", with its MultiCloud database revenue continuing to grow at more than 100%.
In addition, Catz was expected to say that Oracle had signed multiple large cloud services agreements, including one that is expected to contribute more than $30bn (£21.9bn) in annual revenue starting in the 2028 financial year, but did not name the customer.
Read more: FTSE 100 LIVE: Stocks rise while pound and UK bonds recover as Starmer backs Reeves
Bloomberg reported on Wednesday that OpenAI had agreed to computing power from Oracle data centres as part of the Stargate initiative, citing people familiar with the work. This would reportedly total 4.5 gigawatts of data centre power in the US.
According to one of the sources, the Stargate agreement makes up at least part of the $30bn contract disclosed in the SEC filing on Monday.
A spokesperson for Oracle had not responded to Yahoo Finance UK's request for comment at the time of writing.
US-listed shares in TSMC (TSM) rose around 4% on Wednesday after Needham raised its price target on the chipmaker from $225 to $270 per share.
TSMC, which is the world's largest contract chipmaker, also got a boost from reports that Intel's recently appointed CEO was considering a major shift in its chip manufacturing process.
Read more: Pound recovers as Starmer eases market panic over chancellor
Reuters reported that Intel (INTC) CEO Lip-Bu Tan was considering scrapping the American chipmaker's efforts for the 18A manufacturing process, which included enhancements that were meant to enable the company to compete with TSMC's capabilities.
Instead, Intel is reportedly exploring a change to the contract manufacturing business, which would mean offering outside customers a newer generation of technology. Reuters reported that analysts believe this process would be more competitive against TSMC in aiming to land key customers, such as Apple (AAPL) or Nvidia (NVDA).
Another tech stock in focus on Thursday was Rigetti Computing (RGTI), after it surged 15% in the previous session.
The jump came after Cantor Fitzgerald analyst Troy Jensen initiated a "overweight" rating on the Rigetti, along with two other quantum computing companies, according to a Barron's report.
Jensen reportedly said that the competitive ecosystem of quantum computing "positions Rigetti to benefit from the efforts of others". He also initiated "overweight" ratings on D-Wave (QBTS) and IonQ (IONQ).
On the London market, shares in Currys (CURY.L) jumped 7.5% on Thursday morning, as the electronics retailer reported stronger sales and profits for the past year.
Currys posted group adjusted profit before tax of £162m ($221m), which was up 37% year-on-year, while group revenue of £8.7bn was up 3%.
In addition, the company said trading in the early part of the new financial year has been in line woth expectations.
Stocks: Create your watchlist and portfolio
Dan Lane, lead analyst at Robinhood UK, said: "What a year for Currys. Profits before tax are in rude health and net cash of £184m gives the balance sheet a solid basis to make even bigger strides this year.
"UK consumer confidence is growing and if it has bottomed, Currys could benefit even more from Britons feeling happier to spend on bigger electrical purchases. Inflation is subsiding and while wage growth is slowing, consumers are clearly considering the worst hits to their pockets to be behind them."
FTSE 250-listed (^FTMC) company Watches of Switzerland (WOSG.L) fell 6.4% on Thursday morning, after the retailer reported a fall in annual pre-tax profits.
Watches of Switzerland reported record revenue of £1.65bn for year ended 27 April, which was up 8% year-on-year. However, statutory profit before tax was down 18% to £76m.
Barclays analysts, which have an "overweight" rating on the stock, said in a note on Thursday that there were "no fireworks" in the results but the fact that the company's guidance is close to consensus is "reassuring".
Read more: Stocks that are trending today
They said: "Whilst we have lowered our forecasts slightly, this is largely FX driven, and the mid-point of the company's guidance (at constant currency) is close to company consensus. We do not believe that these results move the investment debate on substantially. We now forecast PBT (profit before tax) in FY26 of £137m, a fraction higher than £136m reported in FY25."
"This is clearly a long way off the growth delivered during the company's stronger years, but given the potential headwinds from tariffs, we believe that if broadly flat profits can be delivered, it would remove some of the more significant downside scenarios and investor concerns," Barclays' analysts added.
Read more:
'Too soon' to see price effects from tariffs, says Bank of England's Bailey
Global economy to slow amid 'most severe trade war since 1930s', says Fitch
UK economy grew 0.7% in first quarter of the yearInicia sesión para acceder a tu cartera de valores
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating
Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating

Yahoo

time10 minutes ago

  • Yahoo

Guggenheim Raises GeneDx (WGS) Price Target, Maintaining a Buy Rating

GeneDx Holdings Corp (NASDAQ:WGS) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Guggenheim analyst Subbu Nambi has raised the price target for GeneDx Holdings Corp (NASDAQ:WGS) from $88.00 to $115.00, reinforcing a bullish stance on the company's long-term trajectory. The 'Buy' rating remains unchanged, signaling confidence in GeneDx's market position and its potential to capture a growing share of the precision medicine space. A modern office space where the team is engaging in business development and management services. GeneDx, known for its deep expertise in rare disease genomics and next-generation sequencing, is emerging as a leader in healthcare innovation. The company blends advanced bioinformatics with clinical expertise to help physicians diagnose complex, genetically driven conditions more efficiently. Its platform leverages massive datasets and machine learning algorithms to interpret whole-genome and exome sequencing, placing it squarely in the center of the healthcare AI movement. The price target hike reflects Guggenheim's view that GeneDx is well-positioned to benefit from the increasing demand for personalized medicine and the broader integration of data-driven tools in clinical care. As health systems and biopharma partners seek faster, more accurate diagnostic solutions, GeneDx's technology and scalable infrastructure make it a critical player in the shift toward AI-enabled healthcare. With momentum building across both clinical and commercial channels, the company appears to be gaining traction at a pivotal time for genomic medicine. The revised valuation underscores growing investor recognition of GeneDx's role in transforming how rare and complex diseases are diagnosed and managed. While we acknowledge the potential of WGS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WGS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio

Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating
Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating

Yahoo

time10 minutes ago

  • Yahoo

Morgan Stanley Raises iRhythm (IRTC) Price Target, Maintains Overweight Rating

iRhythm Technologies, Inc. (NASDAQ:IRTC) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Morgan Stanley has raised its price target on iRhythm Technologies, Inc. (NASDAQ:IRTC) to $160 from $130, while maintaining an 'Overweight' rating, citing strong early indicators for the company's second-quarter performance. In a recent note to investors, the firm pointed to a surge in MyZio app downloads, which totaled 171,169 in Q2—up 74% year-over-year and 36% compared to the first quarter. The increase suggests iRhythm may outperform Street estimates, as most of the Zio patches generating revenue for the quarter have already been prescribed and tied to active monitoring. A patient being monitored with a portable ECG device, showing the effectiveness of the company's products. Morgan Stanley highlighted that the strong app adoption signals growing patient engagement and broader acceptance of digital cardiac care, which bodes well for both short- and long-term growth. With scalable infrastructure and a rising volume of clinical data feeding its algorithms, iRhythm is not only improving detection but also redefining remote patient monitoring. As healthcare shifts toward personalized, tech-driven models, iRhythm's innovation and execution place it among the leaders in digital diagnostics. Morgan Stanley views the company as a compelling investment amid increasing demand for smart, connected health solutions. iRhythm Technologies, Inc. (NASDAQ:IRTC) develops and markets the Zio platform, a patch-based cardiac monitoring solution that leverages advanced analytics and machine learning to detect arrhythmias with clinical-grade accuracy. The company's AI-enabled technology analyzes millions of heartbeats in real time, helping physicians diagnose conditions like atrial fibrillation more effectively than traditional methods. While we acknowledge the potential of IRTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRTC and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Sign in to access your portfolio

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505
Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

Yahoo

time10 minutes ago

  • Yahoo

Schrödinger (SDGR) Receives FDA Fast Track Designation for Cancer Drug SGR-1505

Schrödinger, Inc. (NASDAQ:SDGR) is one of the top 10 healthcare AI stocks to buy according to hedge funds. Schrödinger, Inc. (NASDAQ:SDGR) announced that its investigational drug SGR-1505 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of adults with Waldenström macroglobulinemia who have not responded to at least two prior therapies, including a Bruton's tyrosine kinase (BTK) inhibitor. The designation is designed to expedite the development and review of drugs that address serious or life-threatening conditions with unmet medical need. A biopharmaceutical executive discussing plans with a government laboratory. SGR-1505 is a selective MALT1 inhibitor currently in clinical development. Waldenström macroglobulinemia is a rare type of non-Hodgkin lymphoma, and treatment-resistant forms present significant challenges for patients and clinicians. Schrödinger's approach to drug discovery gives it a unique advantage in targeting such difficult diseases. The company is best known for its computational platform that integrates physics-based modeling and advanced algorithms to design novel compounds with greater precision and efficiency. This model-driven strategy makes Schrödinger one of the few healthcare companies at the forefront of computational drug discovery—a field that blends molecular science with cutting-edge software to identify and optimize potential therapies faster than traditional methods. With the FDA's Fast Track status, SGR-1505 may benefit from more frequent interaction with the agency and potential eligibility for accelerated approval, positioning Schrödinger to advance an important treatment option while reinforcing its growing role as a technology-driven innovator in the pharmaceutical sector. While we acknowledge the potential of SDGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SDGR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Best Biotech Stocks To Invest In Now and 12 Best Healthcare Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store